DEF 14A: Supernus Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting

Supernus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 16, 2025, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Summary

• Supernus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 16, 2025.
• Stockholders will vote on the election of two directors, the approval of executive compensation, and the ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
• The record date for determining stockholders eligible to vote is April 22, 2025.
• The company's common stock outstanding as of April 22, 2025, was 55,989,623 shares.
• The Board of Directors recommends voting for the election of Carrolee Barlow and Jack A. Khattar as directors.
• The Board of Directors recommends voting for the approval of executive compensation and the ratification of KPMG LLP.
• BlackRock, Inc. beneficially owns 14.6% of the common stock, The Vanguard Group and its affiliates own 11.1%, and Armistice Capital, LLC owns 8.6%.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions. The sentiment is slightly positive due to the routine nature of the items and the absence of any significant negative news.

Positives

• The company is providing a virtual meeting option for stockholders, allowing for broader participation.
• The Board of Directors is actively soliciting proxies to ensure a quorum at the Annual Meeting.
• Stockholders have the option to receive proxy materials electronically, reducing costs and environmental impact.
• The company has a Code of Ethics and Business Conduct applicable to all employees, officers, and directors.
• The Board of Directors has determined that all directors, except the CEO, meet the independence requirements of the Nasdaq Marketplace Rules.

Negatives

• The company is bearing the expense of soliciting proxies for the Annual Meeting.
• The company prohibits directors, officers and employees from pledging Company securities or holding Company securities in margin accounts.
• 9 Meters Biopharma, where Bethany L. Sensenig was Chief Financial Officer and Interim Chief Executive Officer, filed for bankruptcy in July 2023.

Risks

• Failure to achieve a quorum at the Annual Meeting could delay or prevent the company from conducting its business.
• The company's reliance on a virtual meeting format may present technical challenges for some stockholders.
• The company faces the risk of potential conflicts of interest between directors and the company or senior management.
• The company faces the risk of cyber-attacks on the Companys systems and network.

Future Outlook

The document outlines the matters to be considered and voted upon at the 2025 Annual Meeting of Stockholders, including the election of directors, approval of executive compensation, and ratification of the independent auditor, providing a glimpse into the company's governance and operational focus for the upcoming year.

Management Comments

• The Board of Directors is soliciting proxies to be used at the 2025 Annual Meeting of Stockholders.
• All of our stockholders are cordially invited to attend the Annual Meeting virtually via webcast.
• Whether or not you plan to attend the Annual Meeting, we urge you to vote your shares at your earliest convenience.
• Submitting your proxy in advance will not affect your right to vote at the Annual Meeting if you attend virtually via webcast.

Industry Context

This proxy statement is a standard document for publicly traded companies, providing transparency and enabling shareholders to participate in corporate governance decisions. The items to be voted on are typical for an annual meeting.

Comparison to Industry Standards

• The structure of the board and its committees (Audit, Compensation, Governance and Nominating) aligns with standard corporate governance practices for publicly traded companies.
• The presence of an independent compensation consultant (Aon) is a common practice to ensure executive compensation is aligned with market standards.
• The disclosure of beneficial ownership by major stockholders is a standard requirement for publicly traded companies.
• The inclusion of a say-on-pay proposal is mandated by the Dodd-Frank Act and is a common practice among publicly traded companies.
• The process for stockholders to communicate with the Board of Directors and submit proposals is consistent with industry norms.

Corporate Governance

Related Party Transactions

• The company employs an adult daughter of Mr. Khattar in a non-executive, managerial capacity as an Associate Director, Marketing.
• This individual earned total compensation for fiscal year 2024 of $182,616 and total compensation for fiscal year 2023 of $177,747, which is commensurate with her peers and exclusive of unvested options awarded to her.

Stakeholder Impact

• Shareholders are provided with information to make informed decisions regarding the election of directors, executive compensation, and the selection of the independent auditor.
• Employees are subject to a Code of Ethics and Business Conduct.
• Executive officers are subject to Share Ownership and Retention Guidelines.
• Directors, officers and employees are prohibited from pledging Company securities or holding Company securities in margin accounts.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 16, 2025, and announce the results of the voting.
• The Board of Directors and management will consider the outcome of the advisory vote on executive compensation in future compensation decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, KPMG, Supernus Pharmaceuticals, Voting, Governance